Rate My Professor Nicholas Farrell

Nicholas Farrell, Ph.D., Professor Emeritus in the Department of Chemistry at Virginia Commonwealth University, joined the faculty in fall 1993 after prior work at the University of Vermont and retired in 2023 following 30 years of service. Educated in Ireland, the United Kingdom, and Canada, he became a prominent figure in Chemistry, specializing in bioinorganic approaches to drug development. Affiliated with VCU Massey Cancer Center, Farrell's career emphasized interdisciplinary collaboration across chemistry, biochemistry, chemical biology, and medical sciences. His laboratory focused on metal complexes in biology and medicine, particularly designing platinum compounds with novel mechanisms to overcome resistance in cancer chemotherapy. A landmark achievement was the development of TriplatinNC (BBR3464), a trinuclear platinum agent—the first nonclassical platinum drug to enter human clinical trials. Licensed to Roche, it underwent Phase I and II trials for ovarian, lung, pancreatic, gastric, and skin cancers, demonstrating potency at lower doses with reduced side effects compared to cisplatin. This work redefined structure-activity relationships in platinum chemistry, expanding beyond traditional mononuclear structures. Farrell's research also explored gold compounds for HIV treatment targeting nucleocapsid proteins and coordination chemistry of zinc finger proteins for antiviral agents. He co-holds over 70 patents worldwide and authored more than 300 peer-reviewed papers and reviews.

Farrell's contributions earned major recognition, including the VCU University Award of Excellence in 2020—one of the university's highest honors—the VCU Distinguished Research Scholarship Award in 2003, appointment as University Professor in 2017, induction into VCU’s chapter of the National Academy of Inventors in 2018, and selection as a Jefferson Science Fellow at the U.S. Department of State. His 1989 book, Transition Metal Complexes as Drugs and Chemotherapeutic Agents, was among the first to systematize the field, covering platinum anticancer agents, gold for arthritis, and others. Through mentoring, especially undergraduates from underrepresented backgrounds, many of whom co-authored publications and advanced to graduate school or chemistry careers, Farrell fostered the next generation. His discoveries have extended and enhanced lives for patients with aggressive cancers, leaving a lasting legacy in oncology and platinum drug development.